{"id":"placebo-to-match-zanamivir","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos are inactive substances used in controlled trials to establish the true efficacy of an active drug by comparison. This particular placebo is formulated to mimic zanamivir (an inhaled antiviral), likely matching its appearance, taste, and administration method to maintain blinding in phase 3 trials. It contains no active pharmaceutical ingredient and produces no therapeutic effect.","oneSentence":"This is an inert placebo formulation designed to match the physical and sensory characteristics of zanamivir for blinded clinical trial comparisons.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:46.015Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in zanamivir clinical trials (influenza)"}]},"trialDetails":[{"nctId":"NCT03684044","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-01-08","conditions":"Influenza","enrollment":363},{"nctId":"NCT01231620","phase":"PHASE3","title":"A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-15","conditions":"Influenza, Human","enrollment":626}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to match zanamivir","genericName":"Placebo to match zanamivir","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is an inert placebo formulation designed to match the physical and sensory characteristics of zanamivir for blinded clinical trial comparisons. Used for Control arm in zanamivir clinical trials (influenza).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}